Figure 5. Changes in the self-rating Beck Depression Inventory (BDI; left) and the 21-item Hamilton Depression Rating Scale (HAMD; right) during and after treatment with the nonpeptidergic CRHRI antagonist R121919 (formerly called NBI-30775) and the selective serotonin … Nevertheless, extrapolating the aforementioned hypothesis, it cannot be excluded that, Inhibitors,research,lifescience,medical apart from CRHRl hyperfunction, a condition of CRHR2 hypofunction may exist in depressed patients. Due to impaired CRHR2-mediated anxiolysis, the subject might remain in an extended state of anxiety and arousal.

Possibly, other stress recovery processes could also be impaired by the defunct CRHR2, including HPA regulation Inhibitors,research,lifescience,medical and autonomic processes.17,51-53,93,94 Figure 4 present a working hypothesis based on an integration of the previously described issues. Our hypothetical model basically proposes a mechanism in which the development of anxiety and mood disorders is caused

by a shift in the balance between the effects of the hippocampus and the central amygdaloid nucleus initially on the HPA axis, but eventually also on the nucleus accumbens and frontal cortex, Inhibitors,research,lifescience,medical brain regions involved in the regulation of affective states. The altered state of amygdaloid output is also expected to affect autonomic outflow which, in combination with the enhanced glucocorticoid secretion, Inhibitors,research,lifescience,medical could be responsible for the physiological, metabolic, and immune disturbances often seen in depressed and anxious patients. The CRH neuropeptide family

and their receptors are major participants in this network and, with the recent growth of this family (ie, Ucn II and Ucn III), a major step Inhibitors,research,lifescience,medical has been made toward the elucidation of the roles of CRHRl and CRHR2 in anxiety and depression. Concluding remarks Overall, the ABT-263 datasheet pattern that is emerging is one of a network subserving the acute and the recovery phase of the stress-coping response. Recent advances with regard to the growth of the CRH neuropeptide family, the dual function of CRHR1 and CRHR2 in anxiety and HPA regulation, and the CRH-MR regulatory during shunt in HPA axis control have provided the cornerstones for a significant leap in our understanding of the wiring and timings of the stress-coping response. Of utmost importance here is the acquired knowledge about the stress defense mechanisms underpinning anxiolysis, HPA control, and autonomic stability. These advances open the way for the development of novel classes of antidepressant drugs not just targeting the acute response systems, but also acting as supports to the stress defense mechanisms. To address this goal, substantial investments are required to further elucidate the regulatory pathways and players governing the network both in health and disease.